US FDA Looks For Advisory Panel's Blessing Of Development Pathway For Monoclonal Antibodies In Rabies PEP
Executive Summary
FDA's Division of Antiviral Products proposes a pathway for sponsors to develop monoclonal antibodies designed for rabies post-exposure prophylaxis as an alternative to anti-rabies virus immunoglobulin, but it wants input from an advisory committee before proceeding.
You may also be interested in...
How Do You Improve On A Cure? US FDA Panel Discusses Enrollment Conundrum
When the disease is deadly and the current standard of care is highly effective, would anyone join a clinical trial?
Rabies Monoclonal Antibody Development Plan Gets US FDA Panel Backing
A second-line indication for rabies post-exposure prophylaxis is the best a monoclonal antibody can initially expect, but postmarketing studies could get the product upgraded to first-line status, the Antimicrobial Drugs Advisory Committee suggests as it endorses the US FDA's proposed development plan in two separate 16-0 votes.
Serum Leads Way With Heat-Stable Rotavirus Vaccine But Competition Unfazed
Serum Institute has launched a cut-price oral thermostable rotavirus vaccine in India, but competitors like Hilleman Labs, also developing a heat-stable vaccine in the area, aren’t losing much sleep, for now at least. Serum has also introduced a rabies monoclonal antibody.